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This study investigated the maximum-tolerated dose of gemcitabine based on the frequency of dose-limiting toxicities of
weekly gemcitabine treatment with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Fifteen
patients with locally advanced pancreatic cancer that was histologically conﬁrmed as adenocarcinoma were enrolled in this
phase I trial of weekly gemcitabine (150–350 mg m
72) with concurrent radiotherapy (50.4 Gy in 28 fractions). Gemcitabine
was administered weekly as an intravenous 30-min infusion before radiotherapy for 6 weeks. Three of six patients at the dose
of 350 mg m
72 of gemicitabine demonstrated dose-limiting toxicities involving neutropenia/ leukocytopenia and elevated
transaminase, while nine patients at doses of 150 mg m
72 and 250 mg m
72 did not demonstrate any sign of dose-limiting
toxicity. Of all 15 enrolled patients, six patients (40.0%) showed a partial response. More than 50% reduction of serum
carbohydrate antigen 19-9 level was observed in 13 (92.9%) of 14 patients who had pretreatment carbohydrate antigen 19-9
levels of 100 U ml
71 or greater. The maximum-tolerated dose of weekly gemcitabine with concurrent radiotherapy was
250 mg m
72, and this regimen may have substantial antitumour activity for patients with locally advanced pancreatic cancer. A
phase II trial of weekly gemcitabine at the dose of 250 mg m
72 with concurrent radiation in patients with locally advanced
pancreatic cancer is now underway.
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Pancreatic cancer (PC) is diagnosed at an advanced stage in most
patients, despite recent improvements in diagnostic techniques.
Among these patients, roughly half are diagnosed with locally
advanced disease radiographically conﬁned to the pancreas and
surrounding tissues (Okada, 1999). In the patients with locally
advanced PC, prospective randomized trials conducted by Moertel
et al (1969) and the Gastrointestinal Tumor Study Group (GITSG)
(Moertel et al, 1982; Gastrointestinal Tumor Study Group, 1988)
have demonstrated that the combination of radiotherapy and
chemotherapy (chemoradiotherapy; CRT) resulted in signiﬁcantly
better survival than either radiotherapy alone or chemotherapy
alone. In patients with resectable PC, the randomised controlled
trial conducted by GITSG demonstrated a signiﬁcant survival
advantage for patients receiving adjuvant CRT (Gastrointestinal
Tumor Study Group, 1987), but the European Study Group for
Pancreatic Cancer (ESPAC) trial failed to show the survival beneﬁt
of adjuvant CRT (Neoptolemos et al, 2001). Thus, CRT is presently
accepted as the standard treatment for locally advanced PC
(Okada, 1999), but the role of adjuvant CRT for patients with
resectable PC remains controversial. However, optimal CRT regi-
mens have not yet been determined, although various anticancer
agents and radiation schedules are being examined in clinical trials.
Gemcitabine is a novel deoxycitidine analogue with a broad
spectrum of antitumour activity against a variety of solid tumours
including PC (Abratt et al, 1994; Casper et al, 1994). In patients
with advanced PC, gemcitabine demonstrated a greater clinical
beneﬁt and survival compared with 5-ﬂuoruracil (Bruiss et al,
1997). Gemcitabine has also been shown to be a potent radiosen-
sitizer in human pancreatic and other solid tumour cell lines
(Lawrence et al, 1996; Shewach and Lawrence, 1996; van Putten
et al, 2001), suggesting that the combination of radiotherapy
and gemcitabine may improve survival in patients with locally
advanced PC. Therefore, we conducted a phase I trial to determine
the maximum-tolerated dose (MTD) of gemcitabine based on the
frequency of dose-limiting toxicities (DLT) of weekly gemcitabine




Patients eligible for study entry had histologically or cytologically
conﬁrmed locally advanced nonresectable PC. Eligibility criteria
were: 20–74 years of age; Karnofsky performance status of 50–
100 points; no evidence of distant metastasis, measurable or asses-
sable disease, an estimated life expectancy 58 weeks after study
entry; no prior treatment for PC; adequate haematological function
(haemoglobin 510 g dl
71, leukocytes 54000 mm
3, neutrophils
42000 mm
3, and platelets 5100000 mm
3), adequate hepatic
function (serum total bilirubin 42.0 mg dl
71 and serum transa-
minases (glutamic oxaloacetic transaminase (GOT)/glutamic
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normal limit); written informed consent.
The exclusion criteria were as follows: active infection; severe
heart disease; interstitial pneumonitis or pulmonary ﬁbrosis; pleur-
al effusion or ascites; active gastroduodenal ulcer; severe mental
disorder, active concomitant malignancy; pregnant and lactating
females; females of childbearing age unless using effective contra-
ception; other serious medical conditions.
Ultrasonography, computed tomography of the abdomen, and
chest X-ray were performed as pretreatment staging to assess the
local extension of the tumour and exclude the presence of distant
metastasis. The criteria of computed tomography for the nonresect-
ability of the tumour included tumour encasement of the celiac
trunk and/or superior mesenteric artery, and obstruction or bilat-
eral invasion of the portal vein. All patients with obstructive
jaundice underwent percutaneous transhepatic or endoscopic retro-
grade biliary drainage before CRT.
Treatment schedule
Radiation therapy was delivered through four ﬁelds as a single
course of 50.4 gray (Gy) in 28 fractions over 5.5 weeks, using
10–14 megavolt photons (MM22, Scanditronix, Uppsala, Sweden).
The radiation ﬁeld included the primary tumour and a margin of
1–3 cm covering the regional lymph nodes, and was deﬁned by
treatment-planning computed tomography (GE9800, GE Medical
Systems, Milwaukee, WI, USA) obtained 1 or 2 days before initia-
tion of CRT. Lateral treatments were administered together with
anteroposterior:posteroanterior (AP:PA) ﬁelds so that radiation
to the spinal cord could be limited to 40 Gy.
Gemcitabine was administered intravenously over 30 min start-
ing 2 h before radiotherapy weekly for 6 weeks. The scheduled
dose of gemcitabine was initially 350 mg m
72 per week. However,
because of excessive toxicity at this initial dose level, the treatment
plan was revised to include lower dose levels of 150 and
250 mg m
72 per week. Prophylactic antiemetics were not adminis-
tered. However, in patients who experienced grade 2 or higher
nausea/vomiting, antiemetics including granisetron (Kytril;
SmithKline Beecham, Philadelphia, PA, USA) were permitted
during subsequent administration of gemcitabine.
Patient cohorts had a minimum of three patients at each dose
level. If no DLT was observed in the initial three patients, the
dosage was escalated in successive cohorts. If DLT was observed
in one or two of the initial three patients, three additional
patients were evaluated at that dose level. If only one or two of
six patients experienced DLT, dose escalation would continue.
However, if three or more patients experienced DLT at a given
dose level, then the previous dose level would be considered
MTD. DLT was deﬁned as the following manifestations of toxicity
observed during CRT or within 2 weeks after completing CRT:
grade 3 leukocytopenia and/or neutropenia with high fever, grade
4 haematological toxicities, serum creatinine of 52.0 times UNL,
total bilirubin level of 55.0 times UNL, serum GOT/GPT of 510
times UNL, grade 3 or 4 non-haematological toxicities (excluding
nausea, vomiting, anorexia, fatigue, constipation, alopecia, and
dehydration), two successive weeks’ omission of the administra-
tion of gemcitabine owing to any toxicity, or treatment periods
exceeding 8 weeks.
When DLT or tumour progression was observed during CRT,
CRT was stopped. When grade 3 haematological toxicity, serum
creatinine of 1.5–2.0 times UNL, total bilirubin level of 3.0–
5.0 times UNL, serum GOT/GPT of 5.0–10 times UNL, and/
or grade 2 non-haematological toxicity (excluding nausea,
vomiting, anorexia, fatigue, constipation, alopecia, and dehydra-
tion) were observed, gemcitabine administration was omitted
and postponed to the next scheduled treatment day. The radio-
therapy was also suspended, and then resumed when toxicities
recovered.
Toxicity and response evaluation
The primary end-point of this trial was to evaluate the frequency of
DLT, and the secondary end-point was to evaluate the potential
antitumour activity. Treatment related toxicities were assessed
using National Cancer Institute – Common Toxicity Criteria
version 2.0. During CRT, complete blood count with differential,
serum chemistry, and urinalysis were measured at least once a
week. Tumour response was evaluated at the completion of CRT
and thereafter every 8 weeks until tumour progression, according
to the standard World Health Organization criteria (Miller et al,
1981). Serum carcinoembryonic antigen levels (CEA) and serum
carbohydrate antigen 19-9 levels (CA19-9) were measured monthly
by an immunoradiometric assay. This phase I study was approved
by the Institutional Review Board of the National Cancer Center.
RESULTS
Patients characteristics
Fifteen patients were enrolled in this study from May 2000 to April
2001 at the National Cancer Center Hospital, Tokyo, Japan. The
characteristics of the patients are listed in Table 1. The median
age was 59 (range: 51–74) years. Karnofsky performance status
was 100 in one patient (7%), 90 in 13 (87%), and 80 in 1 (7%).
The median serum CA19-9 level is 1109 (range: 6–16780). Patients
were treated with radiation and concurrent weekly gemcitabine
over three dose levels, as listed in Table 2.
Toxicity
The toxicities observed in the 15 enrolled patients are listed in Table
3. There was no treatment-related death during this study. Three of
six patients treated at the gemcitabine 350 mg m
72 dose level experi-
enced DLT; one patient developed grade 4 leukocytopenia/
neutropenia, a second developed grade 4 serum GPT increase, and
a third required two successive weeks’ omission of gemcitabine
administration due to serum GOT and GPT increase. Moreover,
before DLT was observed in level 1, 8 of 31 planned administrations
were omitted due to adverse effects including leukocytopenia,
neutropenia, GOT/GPT increase, and severe fatigue. Because the
DLTs were observed in three of six patients at the ﬁrst dose level
(350 mg m
72), the protocol was revised and subsequent patients
were enrolled at lower dose levels (gemcitabine dose level 71:
150 mg m
72, level 0: 250 mg m
72). Six patients were enrolled in
level 0 to evaluate the frequency of DLT more accurately, although
no DLT was observed in the initial three patients. One of 18 planned
administrations at level 71 and 4 of 36 administrations at level 0
were omitted due to adverse effects, including grade 3 leukocytope-
nia, grade 3 neutropenia, grade 3 thrombocytopenia, and grade 3
GOT/GPT increase which did not exceed 10 times UNL. However,
these toxicities were mild and transient, and all patients treated at
level 71 or level 0 completed the scheduled course of CRT without
DLT. Gastric ulcer with epigastralgia was observed in one patient
(level 0) 1 week after CRT, but the patient recovered with medical
treatment using omeprazole (Omepral; Astra Zeneca, Sweden). Thus,
weekly gemcitabine at a 150 mg m




Six patients (level 1: 4 patients, level 71: 0 patients, level 0: 2
patients) achieved partial response, giving an overall response rate
of 40.0% (95% conﬁdence interval, 15.2–64.8%), and the mean
duration of response was 7.5 months (range: 3.3–12.3 months).
The remaining nine patients demonstrated stable disease. After
the completion of CRT, the serum CA19-9 level was reduced more
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71 or greater, and the serum CEA level was
reduced more than 50% in four (80.0%) of ﬁve patients who had a
pretreatment level of 10 ng ml
71 or greater (Table 4).
DISCUSSION
Currently, concomitant external beam radiotherapy and
chemotherapy has been accepted as the standard therapy for
patients with locally advanced nonresectable PC (Okada, 1999),
because randomized trials have demonstrated improved survival
with CRT compared with that by either radiation alone or
chemotherapy alone (Moertel et al, 1969, 1981; Gastrointestinal
Tumor Study Group, 1988), although the role of adjuvant CRT
for patients with resectable PC remains controversial. To intensify
the treatment efﬁcacy, various anticancer agents, and radiation
schedules are being examined in clinical trials. However, to date,
optimal CRT regimens have not yet been determined.
Gemcitabine produced signiﬁcantly better clinical beneﬁt
(decreased pain, improved performance status and/or weight gain)
(response rate, 23.8% vs 4.8%) and survival advantage (median
survival, 5.6 vs 4.4 months) compared with bolus 5-ﬂuorouracil in
a phase III trial (Burris et al, 1997), and the similar effects on
disease-related symptoms were documented in patients with 5-ﬂuor-
ouracil-refractory PC (Rothenberg et al, 1996). Moreover, in over
3000 patients with advanced PC treated with gemcitabine, notable
disease-related symptom improvement (response rate, 18.4%) and
survival (median survival, 4.8 months) were also seen (Storniolo et
al, 1999). Therefore, gemcitabine has recently been accepted as the
ﬁrst-line chemotherapy for advanced PC, particularly in Western
countries. In the majority of reported clinical trials including these
trials, gemcitabine was administered once weekly. Gemcitabine has
also been demonstrated in vitro and in vivo to enhance the cytotoxic
activity of radiation (Lawrence et al, 1996; Shewach and Lawrence,
1996), although the precise mechanism of radiosensitization remains
unknown (van Putten et al, 2001). Some clinical trials of gemcita-
bine and concurrent radiotherapy have been reported (Blackstock
et al, 1999; Talamonti et al, 2000), but the optimal dosage for a
weekly gemcitabine schedule has not yet been elucidated. Although
it has been reported that a twice-weekly schedule of gemcitabine is
superior to a once-weekly schedule of gemcitabine for radiosensiti-
zation (Blackstock et al, 1999), the dose of gemcitabine was much
lower (40 mg m
72, twice-weekly) than that used for systemic
chemotherapy. In patients with locally advanced PC treated with
CRT, it is important to enhance the local control and simultaneously
reduce the risk of distant metastases. Therefore, this phase I trial was
designed to determine the MTD of weekly gemcitabine with concur-
rent radiation in patients with locally advanced PC. Eligibility
criteria of this trial included Karnofsky performance status of 50–
100 points. However, all enrolled patients had the Karnofsky perfor-
mance status of 80 or above, because the patients with poor
performance status (e.g. Karnofsky performance status of less than
70) were considered to be intolerable to CRT for fear of the treat-
ment-related toxicities such as fatigue.
We expected that the dose of weekly gemcitabine with concur-
rent radiotherapy would be close to 1000 mg m
72, which is the
standard dose for weekly gemcitabine administration for PC.
However, DLTs involving neutropenia/leukocytopenia and elevated
transaminase were observed in three of six patients at the ﬁrst dose
level (350 mg m









Table 1 Patient characteristics
Number of patients
Characteristics (%)
Age (years) median (range) 59 (51–74)
Gender male 10 (67%)
female 5 (33%)
Karnofsky performance status 100 1 (7%)
90 13 (87%)
80 1 (7%)
Tumour location head 3 (20%)
body-tail 12 (80%)
CEA (ng ml
71) median (range) 4.7 (1.2–98.3)
CA19-9 (U ml
71) median (range) 1109 (6–16780)
CEA: carcinoembryonic antigen; CA19-9: carbohydrate antigen 19-9.
Table 2 Dose schedules of weekly gemicitabine with concurrent radio-
therapy
Dosage level Gemcitabine dose (mg m




*Intravenous infusion over 30 min weekly for 6 weeks.







Grade 1,2 3 4 1,2 3 4 1,2 3 4
Haemoglobin 3 0 0 5 1 0 3 0 0
Leukocytes 2 1 0 2 4 0 2 3 1
Neutrophiles 1 1 0 3 1 0 3 2 1
Platelets 4 0 0 2 2 0 3 0 0
Anorexia 1 2 0 4 2 0 2 2 1
Nausea 2 0 0 4 2 0 4 1 0
Vomiting 1 0 0 4 0 0 5 0 0
Diarrhoea 0 0 0 0 0 0 5 0 0
Fatigue 3 0 0 6 0 0 5 0 0
Gastric ulcer 0 0 0 1 0 0 0 0 0
Total Bilirubin 2 0 0 3 0 0 2 0 0
G O T 20 031 012 0
G P T 20 023 011 1
Alkaline phosphatase 2 0 0 3 0 0 2 0 0













1 1 NC 1.7 1.0 160 710
2 PR (6.0 mo) 11.1 2.7 10740 3718
3 PR (7.7 mo) 1.2 0.7 366 36
4 PR (12.3+mo) 14.5 3.5 7110 82
5 PR (11.9+mo) 3.9 3.4 569 9
6 NC 63.4 1.7 16780 313
71 7 NC 7.2 2.9 908 81
8 NC 1.8 2.4 6 4
9 NC 3.4 3.5 377 90
0 10 NC 3.3 3.0 1349 461
11 NC 9 4.4 101 18
12 NC 4.7 3.5 8580 960
13 PR (3.3+mo) 4 3.3 1109 410
14 PR (3.6+mo) 98.3 14.6 6160 406
15 NC 97.1 50.8 7680 2640
CEA: carcinoembryonic antigen; CA19-9: carbohydrate antigen 19-9; NC: no change;
PR: partial response; mo: months.
aMaximal levels before treatment.
bMinimal levels
after treatment.
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72 per week). All nine
patients treated at the dose of 150 or 250 mg m
72 per week of
gemcitabine completed the scheduled course of CRT without
DLT. In this CRT, the most common toxicities were leukocyotope-
nia and/or neutropenia. However, these toxicities were mild and
transient at level 71 and level 0, and all patients recovered within
a week without any speciﬁc treatment for these toxicities. Anorexia
and/or nausea observed on the day of gemcitabine administration
were the major non-haematological toxicities. However, these toxi-
cities were relieved by prophylactic use of granisetron on
subsequent administration of gemcitabine. Serum GOT/GPT
increase observed at level 0 (250 mg m
72), which was another
major non-haematological toxicity, was also mild and transient.
Therefore, weekly gemcitabine at a dose of 150 mg m
72 or
250 mg m
72 was considered well tolerated, and the MTD was
determined to be 250 mg m
72.
With regard to antitumour activity of weekly gemcitabine with
concurrent radiation, 6 out of 15 patients achieved partial response,
giving an overall response rate of 40.0% (95% conﬁdence interval,
15.2–64.8%). Moreover, the serum CA19-9 level was reduced more
than 50% after the completion of CRT in 13 (92.9%) of 14 patients
with a pretreatment level of 100 U ml
71 or greater. These results
are favourable compared with those of patients treated with CRT
at other treatment schedules (Moertel et al, 1969, 1981; Gastroin-
testinal Tumor Study Group, 1988; Ishii et al, 1997; Blackstock et
al, 1999; Talamonti et al, 2000; Okusaka et al, 2001). To date,
however, there are no data on overall survival and progression-free
survival because of the short follow-up periods. Phase II trial is
required to clarify the antitumour activity and the effect of weekly
gemcitabine with concurrent radiation on survival.
In conclusion, the MTD of weekly gemcitabine with concurrent
radiotherapy was 250 mg m
72, and this regimen may have
substantial antitumour activity for patients with locally advanced
PC. A phase II trial of weekly gemcitabine at a dose of
250 mg m
72 with concurrent radiation in patients with locally
advanced PC is now underway.
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